Page 4 - Yangshi News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Yangshi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Yangshi Today - Breaking & Trending Today
沿着高速看中国|在路上,寻找幸福的味道 - 看点 voc.com.cn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from voc.com.cn Daily Mail and Mail on Sunday newspapers.
沿着高速看中国|在路上,寻找幸福的味道-广西新闻网 gxnews.com.cn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gxnews.com.cn Daily Mail and Mail on Sunday newspapers.
沿着高速看中国丨在路上,寻找幸福的味道 banyuetan.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from banyuetan.org Daily Mail and Mail on Sunday newspapers.
沿着高速看中国丨在路上,寻找幸福的味道_绵阳新闻网 myrb.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from myrb.net Daily Mail and Mail on Sunday newspapers.
Share this article Share this article SHANGHAI, Jan. 6, 2021 /PRNewswire/ Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, announced today that it has initiated the submission of a New Drug Application (NDA) to the Health Sciences Authority (HSA) of Singapore for sacituzumab govitecan-hziy for the treatment of patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease. Breast Cancer is Singapore s number one leading cause of cancer death in women and TNBC accounts for 15-20% of all breast cancer in Singapore. This milestone marks the first of a series of planned NDA submissions for sacituzumab govitecan-hziy in Everest s licensed territory, which also includes Greater China, South Korea, and certain addi ....